CLA Stock Overview
An oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Akari Therapeutics, Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.17 |
| 52 Week High | US$3.90 |
| 52 Week Low | US$0.74 |
| Beta | 0.29 |
| 1 Month Change | 35.26% |
| 3 Month Change | 9.35% |
| 1 Year Change | -10.69% |
| 3 Year Change | -93.97% |
| 5 Year Change | -96.48% |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.6% | -0.4% | 1.4% |
| 1Y | -10.7% | -12.8% | 12.6% |
Return vs Industry: CLA exceeded the German Biotechs industry which returned -12.8% over the past year.
Return vs Market: CLA underperformed the German Market which returned 13.8% over the past year.
Price Volatility
| CLA volatility | |
|---|---|
| CLA Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: CLA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CLA's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 9 | Abizer Gaslightwala | www.akaritx.com |
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) and a novel discovery engine. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate.
Akari Therapeutics, Plc Fundamentals Summary
| CLA fundamental statistics | |
|---|---|
| Market cap | €36.20m |
| Earnings (TTM) | -€17.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs CLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$19.79m |
| Earnings | -US$19.79m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.69 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 14.7% |
How did CLA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 14:29 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Akari Therapeutics, Plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Madhu Kumar | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |